Stanley Druckenmiller's Q2 13F shows Natera as his top holding, surpassing Amazon and Alphabet. The diagnostics firm's oncology growth and cash flow target drive the bet.
Stanley Druckenmiller's Duquesne Family Office made Amazon and Alphabet its most visible Q2 additions. The 13F filing, released Tuesday, shows those two names are not the top of the portfolio. Natera (NASDAQ: NTRA), a molecular diagnostics company, accounted for roughly 19% of the fund's equity holdings as of June 30, a larger weight than any single tech stock.
Natera focuses on cell-free DNA testing across three franchises: women's health, oncology, and transplant monitoring. Its Panorama test screens for genetic conditions in unborn babies. Signatera tracks cancer recurrence through personalized liquid biopsies. Prospera monitors organ transplant rejection. Revenue comes from per-test reimbursement by Medicare, private insurers, and health systems, plus biopharma partnerships.
Growth has been accelerating. In Q1 2026, total revenue hit $696.6 million, up 39% year over year. Oncology test volumes rose 54%. The company processed over one million tests in a single quarter for the first time. Q2 brought $752.8 million in revenue and a gross margin of 64.5%. Total tests reached about 1,043,900, including nearly 297,000 oncology tests. Management raised full-year guidance to a range of $2.85 billion to $2.91 billion and expects cash flow to turn positive for the year.
Signatera is the centerpiece. Natera trained AI models on data from more than 300,000 patients, combining longitudinal blood results, digital pathology, and tumor sequencing. The company secured the first FDA-approved companion diagnostic for blood-based minimal residual disease (MRD), the first PMDA-approved MRD test in Japan, and the first EU IVDR-certified personalized MRD test for solid tumors. A top-tier guideline now recommends Signatera for bladder cancer.
Those milestones give the platform a moat, the filing suggests. Each new cancer indication, guideline, or partnership adds data that competitors cannot easily replicate. The cost of building that moat is visible in the expense line. Natera expects selling, general, and administrative costs of $1.1 billion to $1.2 billion in 2026, with research and development spending of $800 million to $900 million.
Regulatory risk, reimbursement changes, and competition from Guardant Health and Exact Sciences remain. The stock has already risen sharply in 2026, raising valuation questions. The 13F covers positions as of June 30, 2026, and does not disclose entry prices or exit plans.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.